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Background: Acute myeloid leukemia (AML) is initiated and maintained by a subset of self-renewing leukemia stem
cells (LSCs), which contribute to the progression, recurrence and therapeutic resistance of leukemia. However, the
mechanisms underlying the maintenance of LSCs drug resistance have not been fully defined. In this study, we
attempted to elucidate the mechanisms of LSCs drug resistance.
Methods: We performed reverse phase protein arrays to analyze the expression of anti-apoptotic proteins in the
LSC-enriched leukemia cell line KG-1a. Immuno-blotting, cell viability and clinical AML samples were evaluated
to verify the micro-assay results. The characteristics and transcriptional regulation of survivin were analyzed with
the relative luciferase reporter assay, mutant constructs, chromatin immuno-precipitation (ChIP), quantitative
real-time reverse transcription polymerase chain reaction (RT-qPCR), and western blotting. The levels of Sp1,
c-Myc, phospho-extracellular signal-regulated kinase (p-ERK), phospho-mitogen and stress-activated protein kinase
(p-MSK) were investigated in paired CD34+ and CD34- AML patient samples.
Results: Survivin was highly over-expressed in CD34 + CD38- KG-1a cells and paired CD34+ AML patients compared
with their differentiated counterparts. Functionally, survivin contributes to the drug resistance of LSCs, and Sp1 and
c-Myc concurrently regulate levels of survivin transcription. Clinically, Sp1 and c-Myc were significantly up-regulated
and positively correlated with survivin in CD34+ AML patients. Moreover, Sp1 and c-Myc were further activated by
the ERK/MSK mitogen-activated protein kinase (MAPK) signaling pathway, modulating survivin levels.
Conclusion: Our findings demonstrated that ERK/MSK/Sp1/c-Myc axis functioned as a critical regulator of survivin
expression in LSCs, offering a potential new therapeutic strategy for LSCs therapy.
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Acute myeloid leukemia (AML) is an aggressive malignancy
with a-5 year overall survival rate of approximately 30%-
45% in adults and nearly 70% in children [1]. Although the
survival rate in children is quite high, recurrence and
acquired drug-resistance remain the leading causes of* Correspondence: twang-yf@163.com
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unless otherwise stated.death, occurring in over 60% of cases by 1 year after
complete remission [2]. AML is typically a stem cell-driven
disease, and the existence of leukemia stem cells (LSCs)
was first identified (CD34 +CD38-) by JE Dick in 1994;
these cells extremely promote AML progression, chemo-
resistance and recurrence [3,4]. Therefore, identifying
molecules or pathways that are preferentially expressed
in LSCs and determining the principles controlling
AML pathogenesis are critical and may facilitate the
optimization of clinical treatments for AML patients.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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development of novel therapies targeting cancer stem
cells (CSCs), including specific signaling pathways, the
tumor microenvironment, and induction of differenti-
ation and apoptosis [5]. From these studies, survivin has
emerged as an essential factor for tumor progression
and development [6,7]. Survivin, a member of the inhibi-
tors of apoptosis (IAP) protein family, is one of the most
frequently elevated targets in numerous malignancies
and is largely undetectable or expressed at very low
levels in normal and adult tissues. Moreover, survivin
has been linked with poor prognosis, resistance to ther-
apy, and low overall survival [8]. Additionally, survivin is
localized in both the cytoplasm and nucleus and has an
active nuclear transporter in its linker region [9]. Cyto-
plasmic survivin co-operatively interacts with XIAP/
Smac/DIABLO to regulate the caspase cascade function
by directly preventing its release and activation from
mitochondria for the induction of apoptosis [10]. Nuclear
survivin predominantly associates with the Aurora B
kinase/INCENP/Borealin/Dasra B complex to form a
chromosomal passenger, which regulates the progres-
sion of the cell-cycle from the centromere stage to the
mitotic spindle stage during cell division [11,12]. More-
over, survivin has been confirmed to function as an
essential factor in the tumor microenvironment and in
multiple signaling pathways, including PI3K, Akt, p53,
NF-kB, STAT3, Wnt/β-catenin and MAPK, which are
highly involved in controlling tumor maintenance and
growth promotion [13-15].
Survivin has also been shown to be associated with
drug resistance in various cancers or tissues. Park et al
showed that survivin is up-regulated in primary acute
lymphoblastic leukemia (ALL) and plays a critical role in
drug resistance, and inhibition of survivin expression
with chemotherapy leads to the eradication of ALL [16].
Fukuda reported that silencing survivin could signifi-
cantly reduce the proliferation of leukemia cells and
induce apoptosis in FLT3 mutant mice [17]. Intriguingly,
survivin expression is correlated with Oct-4 expression,
allowing concurrently regulation of murine embryonic
stem cell survival under stress [18], demonstrating a
novel function for controlling the stem cell state. These
results suggest that survivin is a potentially worthy
target for personalized molecular therapy. However, the
effects of survivin on the regulating of CSC biological
properties remains to be defined.
In the current study, we aimed to investigate the role
of survivin in LSCs drug resistance and to elucidate the
mechanisms regulating survivin expression in LSCs.
Our results demonstrated that the ERK-MSK-specificity
protein (Sp) 1/c-Myc axis was responsible for survivin
expression, providing valuable targets for further devel-
opment of molecular therapies to treat leukemia.Results
Survivin is highly expressed in LSCs compared with their
differentiated counterparts
Several recent studies have suggested that as much as
25% of cancer cell lines and certain tumor samples have
the properties of CSCs [19]. Therefore, we first isolated
LSCs using magnetic sorting with the gold standard
surface markers CD34 + CD38- from six leukemia cell
lines (Additional file 1: Figure S1A). KG-1a and MOLM13
cells were enriched in LSCs (9.6% and 4.3%, respectively,
Additional file 1: Figure S1B). Subsequently, we identified
the isolated LSCs by examination of typical stem cell gene
expression, cell surface marker ABCB1 (P-gp), which was
preferentially expressed in LSCs [20,21], self-renewal abil-
ity, and drug resistance (using three first-line AML drugs,
Ara-C, Dexamethasone and L-aspartic acid). This analysis
suggested that these cells were indeed LSCs and could be
used for further studies (Additional file 1: Figure S1 and
Additional file 2: Figure S2A).
Next, to demonstrate the specific molecular mecha-
nisms underlying the chemo-resistance of LSCs, we used
the ABC transporter inhibitor verapamil [22] to investi-
gate the dependence of LSCs drug resistance on the
expression of the “drug pump”. As expected, the addition
of verapamil increased Ara-C and dexamethasone-
induced apoptosis (Additional file 2: Figure S2B). How-
ever, the LSCs fractions still showed reduced apoptosis
and higher resistance to chemotherapeutic agents than
non-LSCs subpopulations in KG-1a cells (Additional file
2: Figure S2C). Therefore, we speculated that there might
be other mechanisms mediating drug-resistance in LSCs.
To investigate whether anti-apoptosis-related proteins
were involved in LSCs drug resistance, we performed
reverse-phase protein microarray (RPPA) to analyze the
expression of apoptosis-related proteins in the four pop-
ulations (CD34 + CD38+, CD34 + CD38-, CD34-CD38+,
CD34-CD38-) isolated from KG-1a cells (Figure 1A and
Additional file 3: Figure S3A). Intriguingly, we found
that four apoptosis-related proteins, i.e., Hsp70, survivin,
XIAP, and insulin-like growth factor (IGF)-II, were
highly expressed in CD34 + CD38- cells compared with
other subsets (Figure 1B). Immuno-blotting analysis
yielded similar results as the protein microarray data in
KG-1a cells (Figure 1C). To further investigate which
specific proteins mediated the drug resistance of LSCs,
we used specific short-interfering RNAs (siRNAs). As
shown in Figure 1D, only inhibition of survivin expres-
sion decreased the viability of LSCs consistent with the
observed effects in non-LSCs following addition of
Ara-C, L-Asp, and Dexamethasone, indicating that
survivin could block chemotherapy-induced apoptosis.
Additionally, survivin was also found to be highly
expressed in the LSC-enriched fraction of MOLM13
cells (Figure 1E).
Figure 1 Survivin was highly expressed in leukemia stem cells compared to their differentiated counterparts. (A) KG-1a cells were separated
into four subpopulations, and apoptosis-related protein micro-assays were performed using R statistical programming. (B) The relative expression level
of four apoptosis-related proteins (Hsp70, survivin, XIAP, and IGF-II) were determined (*P < 0.05, **P < 0.01). (C) Protein assay results were confirmed by
western blotting. (D) LSCs and non-LSCs viability was analyzed following inhibition of survivin, Hsp70, XIAP, or IGF-II expression with siRNA in the
presence of chemical agents (Ara-C, L-Asp, and Dexamethasone [Dex]). (E) Analysis of survivin expression in MOLM13 cells following fractionation for
the CD34 + CD38- population. (F) Survivin mRNA expression was analyzed in CD34+/CD34- cells from AML patients (n = 56, *P < 0.05) by real-time
qPCR. (G) Survivin protein expression was analyzed in paired CD34+/CD34- samples from 20 AML patients by western-blot. (H) Line graph showing a
direct comparison of survivin protein levels in CD34+/CD34- cells from paired AML samples (n = 20, *P < 0.05).
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sion in CD34 + CD38- cell fractions was specific for LSCs,
we collected blood samples from 56 patients with AML todirectly compare survivin levels in paired CD34+ and
CD34- cells. Using RT-qPCR, survivin was found to be
significantly up-regulated in primary CD34+ cells from
Zhang et al. Molecular Cancer  (2015) 14:56 Page 4 of 18AML patients (89.3%, 50/56) when compared with their
corresponding CD34- counterparts (P < 0.05, Figure 1F).
Accordingly, direct comparison of survivin protein levels
in 20 paired CD34+ and CD34- samples showed similar
trends for survivin mRNA expression (Figure 1G-1H).
In addition, we found no obvious relationship between
survivin levels and any of the following clinical character-
istics: age, sex, French-American-British (FAB) subtype,
karyotype, white blood cells, platelets, bone marrow (BM)
or peripheral blood (PB) blast counts, and hemoglobin
levels (Table 1).
Survivin contributed to the anti-apoptotic and
chemoresistant characteristics of LSCs
Next, we conducted loss of survivin function to investigate
its contribution to LSCs apoptosis-related characteristics.
Specific siRNAs were used to knockdown survivin, and a
non-targeting siRNA was used as control. CCK-8 assays
showed significant decreases (P < 0.05) in LSCs growth at
24 and 48 h after transfection (Figure 2A). Similarly,
marked survivin knockdown was observed, and cleaved
PARP and caspase3 were obviously increased with
survivin-siRNA 48 h after transfection in both LSC-Table 1 Demographics and clinical characteristics of 56
newly diagnosed AML patients in this study





Female (17) 8 (47%) 9 (53%)
Male (39) 23 (59%) 16 (41%)
P value 0.342
Age
≤40 years old (30) 19 (63%) 11 (37%)
>40 years old (24) 10 (42%) 14 (58%)
P value 0.226
FAB
M0 (5) 3 (60%) 2 (40%)
M1 (12) 10 (83%) 2 (17%)
M2 (8) 2 (25%) 6 (75%)
M5 (23) 17 (74%) 6 (26%)
M7 (8) 1 (13%) 7 (87%)
P value 0.148
Laboratory analysis (median)
WBC (109/L) 16.4 15.8
Platelet (109/L) 87 106
Hemoglobin (g/dL) 9.6 4.3
BM blast, % 36 21
PB blast, % 17 10
P value 0.174enriched cell lines (Figure 2B). Meanwhile, annexin-V/PI
FACS analysis confirmed the obvious increase in apoptosis
at 48 h after siRNA transfection in LSCs (Figure 2C),
suggesting that knockdown of survivin induced apoptosis
in LSCs. Moreover, soft agar colony assays revealed that
knockdown of survivin using survivin-siRNA significantly
decreased colony numbers in KG-1a LSCs compared with
the non-targeting control (43.3 ± 4.8 vs. 145.7 ± 3.2, re-
spectively) and MOLM13 LSCs (38.6 ± 1.7 vs. 150.6 ± 2.3,
respectively; P < 0.05, Figure 2D).
Subsequently, to investigate whether survivin expression
promoted drug resistance, we analyzed drug resistance
AML cell line TS3 (isolated from CD34+ cells), established
from a patient who relapsed despite treatment with
chemotherapy, and used for further experiments. Trans-
duction of primary AML cells (TS3) with a pcDNA-
survivin construct obviously attenuated the effects of
Ara-C, Dexamethasone and L-Asp alone or in combin-
ation on cytotoxicity as compared with controls (P < 0.05),
indicating that over-expression of survivin renders pri-
mary AML cells more resistance to chemotherapeutic
agents (Figure 2E left panel). Conversely, to determine
whether AML cells can be sensitized to chemotherapeutic
drugs, we specifically silenced survivin with si-RNA in
TS3 cells. Non-targeting controls yielded an approxi-
mately 2.5-folder higher IC50 (4.5 μM) than the survivin-
siRNA group (IC50 = 1.8 μM, P < 0.05, Figure 2D right
panel), demonstrating that down-regulation of survivin
could overcome drug resistance in primary AML cells.
Taken together, these results suggested that survivin
contribute to the anti-apoptotic and drug-resistant
characteristics of LSCs, thereby supporting further
investigation of the potential mechanism of survivin
over-expression in these phenotypes.
Survivin promoter region is participated in regulation of
transcription levels
Survivin mRNA is extremely stable in numerous cancers,
and the regulation of this oncogene in tumors can be
linked to translational control [23,24]. Therefore, to deter-
mine whether survivin mRNA (and protein) was also
stable in LSCs, we treated LSCs with the transcriptional
blocker actinomycin Act or the translational inhibitor
cycloheximide (CHX). Survivin mRNA and intracellular
protein levels were largely dependent on regulation of
constitutive transcription and translation, both of which
levels were dramatically reduced after 24 h of treatment in
both LSC cell lines (Figure 3).
To further understand the transcriptional regulation
of survivin in LSCs, we examined the activity of the
promoter from the region ~ 2000 bp upstream of the
transcription start site (TSS). Deletion constructs showed
that promoter activity an increase stepwise (V2 and V3)
or decreased slightly (in V4). Subsequent analysis of the
Figure 2 Survivin knockdown abrogated LSCs growth, induced apoptosis, decreased self-renewal, and sensitized cells to chemotherapy.
(A) Analysis of LSCs viability 24 or 48 h after transfection with survivin-siRNA (*P < 0.05). (B) Analysis of survivin protein expression, cleaved PARP, and
caspase3 expression 48 h after transfection with survivin-siRNA in KG-1a and MOLM13LSCs. Non-targeting (NT)-siRNA was used as negative control.
(C) Analysis of apoptosis rates in LSCs 48 h after transfection with survivin-siRNA (*P < 0.05). NT-siRNA was used as a negative control. (D) Analysis of
the self-renewal capacity of LSCs following knockdown of survivin (*P < 0.05). NT-siRNA was used as a control. (E) Primary AML CD34+ cells (TS3 cells)
were transfected with either pcDNA-survivin vectors or siRNA and treated with combined therapy (left panel) or Ara-C alone (right panel) at the
indicated concentrations (*P < 0.05). Cell viability was detected by CCK-8 assay.
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Figure 3 Survivin expression was controlled by transcription and translation. (A-B) Survivin mRNA and protein expression was determined
after treatment with the transcriptional inhibitor actinomycin D (Act D) in boht LSCs cell lines. (C-D) Survivin mRNA and protein expression was
determined after treatment with the translational inhibitor cycloheximide (CHX) in boht LSCs cell lines.
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lar results in V6 and V7. Interestingly, the V5 construct
(-218 to +170; the shortest construct), exhibited 17.7-
and 7.8-fold transcriptional activity in KG-1a-LSCs and
Non-LSCs respectively, compared with the empty pGL4.7
vector control (Figure 4A).
The robust promoter activity obversed for the V5
sequences suggested a role for this core region in regulat-
ing survivin transcription. We next analyzed this regionfor transcription factors that could regulate survivin ex-
pression and identified several putative transcription
factor-binding sites (Figure 4B). To verify which motifs
mediated the transcriptional activity of the survivin
promoter, substitution mutations of these individual
sites (TCF4, KLF5, Sp1 and c-Myc) were prepared (primers
for mutation are listed in Additional file 4: Table S2).
Abrogation of individual sites repressed transcriptional
activity by 30% and 50% in the MutE and MutH sites,
Figure 4 Identification and characterization of survivin core promoter region. (A) Relative luciferase activity of different survivin promoter
constructs (5′-deletion and 3′-deletion) in KG-1a-LCSs and non-LSC subpopulations. The cells were transfected with 1 μg of promoter plasmid
along with 50 ng of β-actin-Renilla luciferase plasmid as control. (B) The core promoter region of survivin was identified (-218 to +170), and
several transcription factor binding sites were predicted using Mat-Inspector and Jaspar (underlined regions). The arrow denotes the start site of
survivin transcription, and the initiation codon ATG is shown in bold and italicized font. (C) Mutation of each transcription factor binding site was
performed for identification of potential trans-activation motifs. Luciferase assays showed changes in promoter region activity for the mutants
versus wild-type construct (*P < 0.05; **P < 0.01). (D) Mutant E and mutant H are c-Myc and Sp1 binding sites, respectively; the sequences of the
two motifs are shown. All graphs represent at least triplicate independent experiments.
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scriptional activity by 85% compared with the wild-type
promoter V5 sequence in KG-1a-LSCs. Moreover, none
of the other mutant sites showed significant decrease in
transcriptional activity as compared with the control(Figure 4C). Subsequently, we found that MutE and MutH
represented the canonical E-box site (c-Myc sites) and
tandem GC boxes (Sp1 sites) in the V5 promoter region
(Figure 4D), indicating its vital function for transcription
regulation.
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transcription in LSCs
To verify whether Sp1 and c-Myc could truly interact
with the survivin promoter in vivo, we conducted chro-
matin immune-precipitation (ChIP) assays by incubating
KG-1a-LSC cell nuclear extracts in the presence of anti-
Sp1 and anti-c-Myc antibodies or IgG (as a negative
control). ChIP primers for Sp1 (-117/+89) and c-Myc
(-218/-15) were designed to amplify promoter regions
containing putative binding sites; the distal region
primers were used as a negative control. As shown in
Figure 5A, ChIP with antibody against Sp1 and c-Myc
cross-linked to the both binding site cluster, showed an
enrichment of the survivin promoter compared with the
IgG control in KG-1a-LSCs. The ChIP-qPCR also exhib-
ited the similar results with the same primers (Figure 5B).
To further investigate the roles of Sp1 and c-Myc in
the regulating of survivin promoter activity, ectopic over-
expression of pcDNA-Sp1 and pcDNA-Myc co-transfected
with the promoter construct V5 in KG-1a-LSCs and
MOLM13-LSCs resulted in distinct elevation in luciferase
activities compared to cells transfected with empty vector
(Figure 5C and Additional file 3: Figure S3C). Conversely,
we used mithramycin A (MITA), an inhibitor of Sp1 and
c-Myc, which inhibits transcriptional activation by pre-
venting Sp1 from binding to GC-rich regions and blocking
c-Myc expression [25], to elucidate these two motifs at
various concentrations for 48 h. Promoter activity was
significantly attenuated in MITA-treated cells from both
cell lines (Figure 5C, lower panel). Specific siRNA-Sp1/c-
Myc was also confirmed the marked decrease in luciferase
activities of V5 construct in both LSCs cell lines, non-
target siRNA was used as control (Figure 5D). Consistent
with this, survivin protein expression was suppressed after
treatment with MITA in a concentration-dependent man-
ner (Figure 5E). Moreover, ChIP assays demonstrated that
MITA could repress Sp1 and c-Myc in transcription level
(Figure 5F). Taken together, these results indicated that
Sp1 and c-Myc could directly bind to the predicted sites
in the survivin core promoter region V5 and were crucial
for the transcriptional activation of survivin expression.
c-Myc required functional Sp1 binding sites for
transcriptional regulation of the survivin promoter
To comprehensively identify whether these two factors
contributed equally or display different degrees of trans-
activation of the survivin promoter, point mutations
were created in both Sp1 and c-Myc, and mutant con-
structs were transfected alone or in combination into
KG-1a and MOLM13-LSCs (Figure 6A). As shown in
Figure 6B, we observed ~50% and ~40% decreases in
promoter activity in the elements carrying a mutant
GC-box region (Sp1) or E-box region (c-Myc), and
combination mutants result in a nearly 80% decrease inluciferase activity, as compared with the wild-type pro-
moter V5 -218/+170 in both cell lines. Next, we further
investigated the interplay between Sp1 and c-Myc in
survivin promoter. When c-Myc was over-expressed in
the presence of a mutated Sp1 binding site, evaluation
of luciferase activity revealed that the V5 promoter was
not significantly activated as compared with the empty
pcDNA vector control (Figure 6C). These data indi-
cated that mutation of the Sp1 binding site affected the
transcriptional activation of c-Myc. In contrast, Sp1
over-expression was significantly increased by ~2-fold
in the presence of mutated c-Myc sites (P < 0.05), and
the increased activation was similar with that of the
wild-type promoter relative to the empty pcDNA vector
control (Figure 6D). Thus, mutation of the c-Myc binding
site did not affect transcriptional activation by Sp1. In
general, these results revealed that Sp1 possessed the pre-
dominantly role in transcriptional regulation of the survi-
vin promoter, and that the downstream function of c-Myc
mainly depended on the integrity of Sp1 binding sites.
Inhibiting Sp1 and c-Myc-dependent survivin expression
caused chemo-sensitization
To determine whether inhibit of Sp1 or c-Myc could
sensitize LSCs to anticancer drug-induced cyto-toxicity,
we incubated KG-1a and MOLM13-LSCs with MITA in
the presence of Ara-C (5 μM) for 3 days and measured
the percentage of apoptotic cells using flow cytometry
analysis. As shown in Additional file 5: Figure S4A and
S4B, MITA substantially increased the Ara-C induced
apoptosis from 49.7% to 76.3% in KG-1a-LSCs and
46.4% to 63.6% in MOLM13-LSCs. Intriguingly, MITA
also substantially reduced the tumor-sphere-forming abil-
ity in the presence of Ara-C in LSCs compared with the
MITA only and Ara-C only groups (P < 0.01, Additional
file 5: Figure S4C). In other words, MITA combined with
chemotherapeutic drugs could effectively reduce the self-
renewal of LSCs, which represent for tumor unlimited
proliferation and recurrence. Consistent with this, MITA
distinctly repressed luciferase activity in the presence of
Ara-C compared with DMSO in both cell lines (P < 0.05,
Additional file 5: Figure S4D). Collectively, these results
indicated that inhibiting Sp1 and c-Myc-dependent survi-
vin expression could cause chemo-sensitization in LSCs,
suggesting that survivin could be an effective target for
further clinical applications for AML treatment.
High expression of Sp1 and c-Myc in CD34+ AML samples
correlated with Survivin expression
To understand the clinical significance of Sp1 and c-Myc,
paired CD34+ and CD34- cells from 56 AML patients
were analyzed, and relative mRNA levels were determined
as shown in Figure 7A. Both Sp1 and c-Myc were substan-
tially up-regulated in CD34+ AML samples compared
Figure 5 Sp1 and c-Myc activated survivin transcription in LSCs. (A) Chromatin immune-precipitation was used to analyze the binding
of Sp1 and c-Myc to the survivin promoter. Input was used as a positive control. (B) ChIP-qPCR was used to confirm the results shown in (A)
(**P < 0.01). (C) Transcription activities of survivin was analyzed following over-expression of Sp1 and c-Myc vector in KG-1a and MOLM13-LSCs
(*P < 0.05). The cells were co-transfected with the pcDNA-survivin vector, core promoter V5, and Renilla luciferase plasmid as a control. Cells were
also treated with MITA to analyze the effects of Sp1 inhibition on survivin promoter activity. (D) Specific siRNA-Sp1/c-Myc was performed to assess
the effects of these two motifs on survivin luciferase activities. (E) Survivin protein levels were analyzed in LSCs following treatment with MITA at
50, 100, or 200 nM. (F) ChIP assays were used to determine whether MITA could directly inhibit Sp1 and c-Myc binding to its specific sites. All
data are shown as the means ± SDs of results from three experiments.
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Figure 6 c-Myc required functional Sp1 binding sites to activate survivin transcription. (A) c-Myc and Sp1 mutant constructs used for
this study. (B) The effects of mutation of Sp1, c-Myc,and combined mutation of the two motifs on the relative luciferase activity of the wild-type
V5 promoter in KG-1a and MOLM13LSCs. The mutant and wild-type constructs were transfected along with Renilla luciferase plasmid as control
(*P < 0.05, **P < 0.01). (C) The effects of c-Myc over-expression on survivin promoter activity in the context of mutated Sp1 binding sites. The
mutant Sp1 site constructs were co-transfected with pcDNA-c-Myc or empty vector and Renilla luciferase plasmid. Luciferase assays were performed
48 h post-transfection. (D) The effects of Sp1 over-expression on survivin promoter activity in the context of mutated c-Myc binding sites. All
transfection conditions were performed as previous described.
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(45/56) and 64% (36/56) of the CD34+ cells displayed
more than 2.2-fold higher expression of Sp1 and c-Myc
than that by the CD34- cells. On average, Sp1 and c-Myc
levels were elevated by 3.5- and 2.3-fold, respectively, in
CD34+ AML samples (Figure 7B).
On the basis of the above observations, we next investi-
gated whether Sp1 and c-Myc were expressed consistently
with survivin in CD34+ AML patient samples. Linear
regression analysis demonstrated a positive correlation
between the mRNA levels of both survivin and Sp1
(P < 0.05, r = 0.826) and c-Myc (P < 0.035, r = 0.731) in
CD34+ AML samples (Figure 7C and D). We then
determined the protein levels of Sp1, c-Myc and survivin
in 56 AML patients by immuno-blotting (quantification
by Quality One software, high expression was calculated
as more than 2 folder compared with CD34- parts, and
low expression was calculated as less than 0.5 folder, data
not shown). As shown in Figure 7E and F, there were 33
and 28 specimens that showed high expression of both
Sp1/c-Myc and survivin, and 7 and 9 specimens that
showed low expression of both Sp1/c-Myc and survivin.
Evaluation these datas with Fisher’s exact test revealed
that significant correlations between survivin protein
levels and Sp1/c-Myc protein levels in CD34+ AML
specimens (P = 0.024 and P = 0.039, respectively). Col-
lectively, these results suggested that Sp1 and c-Myc
over-expression in CD34+ AML samples regulatedsurvivin transcription, and that both the mRNA and
protein levels of Sp1 and c-Myc were positively corre-
lated with survivin expression.
The ERK/MSK MAPK pathway was constitutively active in
primary CD34+ AML samples and was required for Sp1
expression
Because survivin transcription was mainly regulated by
Sp1, we next examined pathways that regulate Sp1 in
LSCs. Various signaling pathways, including the MAPKs,
have been linked to the expression of Sp1 in multiple
cancers. Therefore, inhibitors of the ERK (U0126), JNK
(SP600125), and p38 (SB203580) pathways were used to
characterize the potential role of MAPKs in the consti-
tutive expression of Sp1. As shown in Figure 8A, only
the ERK inhibitor (U0126) markedly reduced Sp1 pro-
tein expression, whereas JNK and p38 inhibitors did not
significantly affect Sp1 protein levels. To determine which
molecules were involved in signaling downstream of the
ERK MAPK pathway to modulate Sp1 gene expression,
the phosphorylation of MSK, which can be activated by
MAPK/ERK and p38, was analyzed in six paired CD34+
and CD34- AML patients. As expected, phosphorylated-
ERK, phosphorylated-MSK, and Sp1 were obviously con-
stitutively active in all CD34+ fractions (Figure 8B) and
were upregulated by 4.8-, 2.0-, and 1.7-fold on average,
respectively (Figure 8C). To investigate whether ERK
activated phosphor-MSK, we used tumor necrosis factor
Figure 7 Expression of Sp1 and c-Myc in CD34+ AML patients and correlations with survivin levels. (A) A total of 56 paired CD34+ and
CD34- AML patient samples were collected. For each sample, the expression levels of Sp1 and c-Myc were determined by RT-qPCR and normalized to
GAPDH as an internal control. (B) The relative expression of each sample is illustrated. The scatter dot plot shows the relative levels of Sp1 and c-Myc
in CD34+ and CD34- cells from AML patients. (C-D) Correlations among survivin, Sp1, and c-Myc mRNA levels in CD34+ AML patients, as determined
using RT-qPCR and Spearman’s analysis. (E-F) Correlations among survivin, Sp1, and c-Myc protein levels CD34+ AML patients (n = 56), as determined
using Fisher’s exact probability test.
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Figure 8 Constitutive activation of the ERK/MSK/Sp1 axis was required for survivin expression in CD34+ AML samples. (A) LSCs were
treated with the JNK inhibitor SP600125 (0, 25, 50, or 100 μM), the ERK inhibitor U0126 (0, 25, 50, or 100 μM), or the p38 inhibitor SB203580 (0, 5,
10, or 20 μM) for 48 h, and survivin protein expression was analyzed by immune-blotting. (B) The phosphorylation levels of ERK and MSK, as well
as the protein expression level of Sp1, were analyzed in six paired CD34+ AML samples by immune-blotting, and GAPDH was used as an internal
control. (C) The density of each protein band was quantified, and the lines indicate the tendency of altered levels of p-ERK, p-MSK, and Sp1 in
each paired sample. (D) Analysis of MSK activation following treatment with TNF-α or the ERK inhibitor U0126. (E) Analysis of Sp1 activation
following stimulation with TNF-α or the ERK inhibitor U0126. Results were confirmed using the NT-KD MSK vector and the WT MSK vector.
(F) Analysis of survivin mRNA following treatment with TNF-α, U0126, or NT-KD MSK in LSCs (*P < 0.05, **P < 0.01).
Zhang et al. Molecular Cancer  (2015) 14:56 Page 12 of 18(TNF)-α, a specific activator of ERK, and U0126, a specific
inhibitor of ERK. The result showed that MSK phos-
phorylation was elevated after TNF-α stimulation in aconcentration-dependent manner (Figure 8D upper panel).
In contrast, pretreatment with 20 μM U0126 mark-
edly inhibited TNF-α-induced MSK phosphorylation
Zhang et al. Molecular Cancer  (2015) 14:56 Page 13 of 18(Figure 8D lower panel), indicating that MSK was regu-
lated by ERK.
Furthermore, because MSK mediates cytokine-induced
Sp1 phosphorylation at Thr453 [26], we next examined
whether TNF-α could induce the phosphorylation of
endogenous Sp1 via the ERK/MSK pathway using a
phospho-specific Sp1 Thr453 antibody. Substantial phos-
phorylation of Sp1 was observed upon stimulation with
TNF-α (Figure 8E upper panel). Subsequently, we con-
structed a vector-encoding mutant MSK (NT-KD), in
which the N-terminal kinase domain was inactivating by
a point mutation, and a vector encoding wild-type MSK.
Pretreatment with U0126 or NT-KD MSK markedly
inhibited the phosphorylation of Sp1 as compared with
the WT MSK vector,and histone H3 was used as control
(Figure 8E lower panel). Additionally, the survivin mRNA
level was significantly up-regulated by TNF-α and W/T
MSK vector when compared with NT-KD (P < 0.01,
Figure 8F upper panel). Conversely, transfections of W/T
MSK vector could partly alleviate the decreased mRNA
level caused by U0126 in both cell lines 48 h after treat-
ment (P < 0.05, Figure 8F lower panel). Taken together,
our data supported that constitutive activation of the
ERK/MSK/Sp1 axis (as shown by phosphorylation of the
pathway components) was required for over-expression of
survivin in CD34+ AML patients, and finally permitting
the evolution to the “Seed cell” in acute myeloid leukemia
(Figure 9).
Discussion
AML is typically a stem cell-related disease, and the
existence of LSCs was the first identified in tumor-
initiating cells. Strategies to target such cells, which have
been shown to be resistant to conventional treatments,
are expected to greatly improve clinical outcomes and
overall survival rates [27]. Our data presented hereinFigure 9 The proposed mechanism for survivin overexpression in LSC
activates ERK/MSK/Sp1 pathways. This activation, together with c-Myc, conc
allowing LSCs escape from apoptosis (B), and finally permitting the evoluti
represented activation, the dotted arrow represented none affection, and Tdemonstrated that survivin was highly expressed specif-
ically in LSC-enriched fractions and in approximately
85% of CD34+ AML patients compared to their differen-
tiated counterparts, thereby contributing to drug resist-
ance. However, the over-expression of survivin was not
associated with clinical characteristics, such as age, sex,
FAB subtype, or laboratory parameters (Table 1), indicat-
ing that survivin could be an independent factor for
diagnosis or prognosis of AML. Moreover, the expres-
sion of survivin was transcriptionally up-regulated by
Sp1 and c-Myc via the ERK-MSK pathway, and constitu-
tively active (phosphorylated) ERK/MSK in CD34+ AML
patients was required for the phosphorylation (i.e.,
activation) of Sp1, thereby leading to over-expression of
survivin. Thus, we showed for the first time that Sp1/c-
Myc enhanced survivin expression in LSCs via an ERK/
MSK/Sp1/c-Myc-dependent mechanism, maintaining and
promoting chemo-resistance.
Numerous studies, including clinical trials of solid
tumors, acute lymphoblastic leukemia (ALL), and large
B-cell lymphoma, have shown that survivin is an important
target in various cancers. Nakahara T et al. [28] proposed
that targeting survivin with the novel small-molecule
inhibitor YM155 could obviously suppress the growth of
primary prostate tumor xenografts in vivo. Additionally,
Kwee J. K et al. [29] reported that survivin could induces
mitochondrial fragmentation, and reduces mitochondrial
respiration, thereby preventing the accumulation of react-
ive oxygen species, inhibiting apoptosis, and promoting
drug resistance. Consistent with these reports, our results
also indicated that inhibition of survivin could dramatic-
ally decrease LSCs growth, induces apoptosis, suppress
self-renewal, and sensitizes cells to chemotherapy. How-
ever, the regulation of survivin expression in CSCs is
poorly understood. Thus, a better understanding of the
regulation of survivin in LSCs is required for thes. (A) TNF-α stimulation leads to transactivation of TNFR, which
urrently regulates survivin expression in LSCs, facilitating LSCs growth,
on to the “Seed cell” in acute myeloid leukemia (C). The straight arrow
BP and RNA PII represented the transcription initiation complex.
Figure 10 Phosphorylation ERK was specific activated in LSCs.
Phosphorylation ERK was intrinsic and spontaneous activated in LSCs,
which led to drug resistance for clinical chemo-agents. In contrast,
the bulk leukemia cells were more sensitive to chemical drugs and
eventually involved in apoptosis.
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found that steady-state expression of survivin required
constitutive transcription and translation in LSCs; there-
fore, we focused on elucidating the mechanism of tran-
scriptional activation in LSCs.
In this study, the cis-acting promoter elements and
respective binding factors required for constitutive activ-
ity of the survivin promoter in LSCs were identified and
characterized. Deletion analysis of the survivin promoter
in LSCs revealed a core region from nucleotide -218 to
nucleotide +170, and Sp1/c-Myc played crucial roles as
potent cis-acting elements to regulate survivin transcrip-
tion during carcinogenesis. Moreover, Sp1 and c-Myc
directly interacted with the core promoter region (-218
to +170) in vivo, and over-expression or knockdown of
either Sp1 and c-Myc significantly enhanced or attenuated
activity of the survivin core promoter (V5) and endogenous
survivin expression, indicating that the high expression of
survivin in LSCs was dependent on the trans-activation of
Sp1 and c-Myc through positioning of these transcription
factors at specific sequence sites.
Sp1, a C2H2-type zinc finger-type transcription factor
that binds GC-rich sequences, was one of the first
eukaryotic transcription factors to be identified and has
been shown to play an important role in the transcrip-
tional regulation of various genes. Its importance is
highlighted by the observation that Sp1-/-knockout mice
exhibit embryonic lethality [30]. Sp1 is ubiquitously
expressed in normal tissues and elevated in tumors, cor-
relating with a wide range of cellular events and different
cell-type roles in transcription procession [31,32]. Here
we found that the constitutive activation of ERK and
MSK was required for Sp1 expression, and phosphoryl-
ation Sp1 was regulated by TNF-α and ERK/MSK signal-
ing, which ultimately activation survivin expression with
c-Myc in LSCs cell lines and clinical specimen. ERK
pathway activation has been shown to play a role in the
stability of transcription factors [33-35], which may also
be the basis for the effects of ERK inhibition on SP1
expression seen in this study. Additionally, our results
also showed that Sp1 expression was significantly up-
regulated in 92% of paired CD34+ AML patients and
correlated with the expression of survivin mRNA and
protein, indicated that Sp1 was a specific and critical
factor mediating survivin expression.
c-Myc is another pivotal trans-activation factor for the
survivin promoter, as identified in our study. Myc pro-
tein belongs to the Max of Bhlh-Zip family, the members
of which bind to E-boxes and regulate transcription of
target genes as obligate heterodimers with a parter
protein [36]. Myc functions as a proto-oncogene and is
frequently up-regulated in a wide range of tumor types,
driving proliferation and tumor progression. Myc is also
known to mediate the reprogramming of somatic cells[37] and participates in regulation of the cell cycle and
stabilization of cell division [38]. In the context of gene
regulation, Myc acts as a weak transcription factor,
facilitating the formation of transcription complexes
[39]. In the present study, we demonstrated that Myc
over-expression promoted activation of the survivin
promoter in LSCs; however, this effect was only mar-
ginal when Sp1 binding sites were mutated, suggesting
that Myc requires functional Sp1 sites to regulate survi-
vin expression. Similarly, c-Myc expression was signifi-
cantly up-regulated in 91% of paired CD34+ AML
patients and correlated with the expression of survivin
mRNA and protein. Taken together, our data suggested
that while Sp1 functioned independently to regulate the
survivin promoter, c-Myc required Sp1 function in
order to participate in the regulation of survivin. Fur-
ther studies are required to determine whether this
cooperation between Sp1 and Myc also functions to
regulate the expression of other oncogenic genes in
cancer.
The MAPK signal pathway (ERK, JNK, p38) is involved
in regulating cell growth, differentiation, environmental
adaptation to stress, inflammatory reactions, and partici-
pated in cancer progression [40]. In this study, we showed
that only the ERK MAPK pathway played a role in the
regulation of Sp1 levels in LSCs, inhibition of JNK or p38
did not affect Sp1 expression. Importantly, ERK and its
downstream signaling mediator MSK were obviously con-
stitutively activated (i.e phosphorylated) in six paired
CD34+ AML patients, suggesting that activation of ERK
and MSK (as observed by phosphorylation levels of these
targets) was intrinsic and spontaneous in such cells and
was required for the expression of survivin in LSCs
(Figure 10). MSK is known to be regulated by the MAPK/
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candidate for the regulation of cytokine-induced phos-
phorylation of transcription factors [41-43]. Interestingly,
we found that MSK activated Sp1 by phosphorylation at
Thr453. Collectively, our results showed that Sp1 activation
was involved in the signaling pathway downstream of
ERK and MSK, mediating TNF-α-induced expression of
survivin.
From our results showing the correlations between
Sp1 and c-Myc levels and survivin expression in CD34+
AML patients, inhibitors of Sp1 and c-Myc may provide
novel therapeutic strategies for the treatment of leukemia.
MITA, an anticancer antibiotic that selectively binds to
G-C-rich DNA domains in the presence of Mg2+ or Zn2+,
inhibits Sp1 transcriptional activity by preventing its bind-
ing into the DNA major grooves. We found that MITA
treatment effectively suppressed survivin promoter activity
and reduced survivin mRNA and protein levels in LSCs.
Moreover, MITA could sensitize LSCs to chemotherapy
(such as Arc-C) and decreased the self-renewal ability of
LSCs, suggesting that MITA may have potential applica-
tions in the treatment of leukemia (Additional file 5:
Figure S4). However, there are also some limits in our
study. First, we should expand the sample sizes to further
elucidate the relationship between survivin, Sp1 and c-
Myc. Second, we only collected blood samples from AML
for these experiments, and bone marrow samples from
AML should also adapt in further investigation for the
subsequent research. Additionally, we observed signifi-
cantly decreased survivin expression and reduced Sp1-
DNA binding activity after treatment with TNF receptor
signaling inhibitors in our preliminary studies (data
not shown). Therefore, the TNFR/ERK/MSK/Sp1/c-Myc
pathway is likely involved in survivin over-expression in
LSCs. Future studies will focus on the upstream signaling
cascades that alternatively contribute to survivin over-
expression.
Conclusion
Our findings may provide new insights into the tran-
scriptional regulation of survivin, and described the
chemo-resistant properties of LSCs, which will facilitate
the development of novel therapy strategies or identifica-
tion of selective biomarker for diagnosis. Further investi-
gations are warranted to definitively confirm survivin as a
marker for AML.
Materials and Methods
Cell isolation, culture, and transfection
The human leukemia cell lines K562, KG-1a, HL-60,
MOLM13, ML-1, and U937 were cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin. KG-1a and MOLM13 cells
were separated and enriched for CD34 + CD38- cells usingmagnetic microbeads (Miltenyi Biotec, Auburn, CA, USA)
and labeled with CD34-PE, CD38-FITC, or isotype control
antibodies. Cells were analyzed and sorted on a Magnetic
Sorter unit, and the purity and viability of isolated cells
were routinely greater than 95%. The siRNA primer
sequences are listed in Additional file 3: Figure S3B and
were custom synthesized by Shanghai Sangon (Shanghai,
China). After transfection, the inhibition efficiency was
examined by western-blotting. Transfections were per-
formed with Lipofectamine TM2000 according to the
manufacturer’s protocol (Invitrogen Co. Carlsbad, CA,
USA). All signal pathway inhibitors or activators were
purchased from Selleck Chemicals.
Patient collection and sample preparation
Peripheral blood (PB) samples were collected from 56
newly diagnosed AML patients after obtaining informed
consent according to the procedures approved by the
Human Experimentation Committee at the Overseas
Chinese Hosptial of Jinan University and Sun Yat-Sen
University Cancer Hospital (Guangzhou, China). The
characteristics of these patients are summarized in
Table 1. Samples were enriched for leukemia cells by using
Ficoll density gradient centrifugation to obtain the mono-
nuclear fraction and when then cryopreserved in freezing
medium consisting of Cryostor CS10 (BioLife Solutions).
Subsequently, CD34+/CD34- cells were separated from
the leukemia-enriched portion by magnetic-activated cell
sorting (MACS; Miltenyi Biotech) after incubation with
anti-CD34 antibodies and IgG controls (BD Biosciences).
The CD34+/CD34- cells were supplemented with B27
(1:50; Life Technologies, Carlsbad, CA, USA), 10 ng/mL
basic fibroblast growth factor (bFGF) and 20 ng/mL
epidermal growth factor (EGF) in DMEM/F12 media.
All cells were incubated at 37°C in a humidified chamber
with 5% CO2.
Reverse phase protein array
KG-1a cell subsets (CD34 +CD38+, CD34 +CD38-, CD34-
CD38+, and CD34-CD38-) were separated and normalized
to a concentration of 1 × 104 cells/μL, and whole-cell lysates
were prepared. The detailed description and procedures of
the protein array (RayBio Human Apoptosis Antibody
Array G Series) methodology, including antibody and
detection steps according to the manufacturer’s protocol.
The slides were incubated for 2 h with validated primary
antibodies in concentrations ranging from 1:250 to 1:1000.
Subsequently, the secondary antibodies were used to amp-
lify the signal for another 2 h, followed by precipitation
of the stable dye. Positive and negative controls were
positioned across the slide at the edge of each sample, as
described below. Finally, the protein expression intensity
level of each spot was measured using MicroVigene soft-
ware (Vigene Tech, North Billerica, MA, USA). All signal
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after standardization and topographic normalization, and
analyses were performed using the R Statistical Program-
ming Environment, version 2.4.2.Quantitative RT-PCR (qRT-PCR) analysis
Total RNA was extracted using TRIzol reagent (Invitrogen)
and reverse transcribed into cDNA. The mRNA level was
evaluated by RT-qPCR with SsoFast Eva-Green Supermix
(Bio-Ras, Hercules, CA, USA) and was analyzed with a
C1000Thermal Cycler (CFX96 Real-Time System, Bio-
Rad). Relative expressionwas normalized to GAPDHas an
internal control. The following PCR conditions were used
on the LightCycler: 95°C for 5 s, 58°C for 5 s, followed by
40 cycles of 95°C for 15 s and 60°C for 1 min in a 10-μL
reaction volume. The primer sequences for RT-qPCR are-
listed in Additional file 4: Table S3.Western blot analysis
Cells were harvested, rinsed twice in ice-cold PBS, and
kept on ice for 30 min in cell lysis buffer containing
1 mM PMSF with constant agitation. Insoluble cell deb-
ris was discarded following centrifugation for 10 min at
12,000 rpm at 4°C. The protein samples were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) on 10% gels and subsequently transferred to
polyvinylidene (PVDF) membranes (Millipore). Immuno-
blotting was performed for survivin, Sp1, c-Myc, c-Jun
N-terminal kinase (JNK), ERK, MSK, and p38, with
GAPDH expression as an internal control.CCK-8 assay
Approximately 5.0 × 103 cells were seeded into each well
of a 96-well plate. The cells were then exposed to vari-
ous concentrations of chemical agents or si-RNA for 24
or 48 h. After incubation, 10 μL CCK-8 was added to
each well and cells were further incubated for 4 h. Cell
viability was evaluated based on absorbance at 490 nm
in a microplate absorbance reader (Bio-Rad).Flow cytometry and Annexin V-FITC/PI staining
CD34 and CD38 expression were assayed by flow cytom-
etry (FACS Calibur, BD Company) using anti-CD34-PE
and anti-CD38-FITC antibodies (BD Company). For
apoptosis assays, cells were harvested at 48 h after drug
treatment or transfection and centrifuged at 1500 × g for
5 min. After addition of 10 μL Binding reagent and
2.5 μL Annexin V-FITC (KeyGEN BioTECH), samples
were suspended in 0.5 mL cold 1× Binding Buffer twice
and stained with 10 μL PI. The percentage distributions
of apoptotic cells were calculated by FlowJo software.Plasmids constructs, transient transfection, and luciferase
assay
The whole promoter region of the human surviving gene
was cloned into the pGL4 plasmid (Promega, Madison,
WI, USA). To generate various 5′-deletion and 3′-deletion
constructs of the surviving promoter, sequences were amp-
lified from genomic DNA isolated from LSCs (Primers for
deletion constructs are listed in Additional file 4: Table S1).
A site-directed mutagenesis kit (Stratagene, Santa Clara,
CA, USA) was used to generate transcription factor bind-
ing site mutant constructs in regions -218 to +170 of the
survivin promoter. LSCs were cotransfected with 20 μg of
the reporter plasmid and 1 μg Renilla luciferase control
vector (Promega) as an internal control for normalization
of transfection efficiency. The cells were then harvested at
24 h after transfection using a Dual-Luciferase reporter
assay system (Promega), according to the manufacturer’s
instructions. The whole gene lengths of Sp1,c-Myc, WT
MSK, and NT-KD MSK were cloned into the pcDNA3.1
vector. Data are presented as the mean ratio for triplicate
experiments.Sphere formation assay
Single LSCs were isolated and cultured for 2 weeks in
methyl-cellulose medium (Stem Cell Technologies) supple-
mented with 20 ng/mL EGF (Sigma-Aldrich, St. Louis,
MO, USA), 10 ng/mL basic fibroblast growth factor (bFGF;
Invitrogen), 4 μg/mL insulin (Sigma-Aldrich), and B27
(1:50, Invitrogen). After treatment with chemical drugs, the
tumor-sphere numbers were counted, and further statistical
analyses were performed. All cell culture was carried out at
37°C in a humidified incubator with 5% CO2.Chromatin immune-precipitation (ChIP) assay
Confluent LSCs were cross-linked with 1% formaldehyde
for 15 min at room temperature. The cross-linking reac-
tion was terminated by the adding of glycine at a final
concentration of 0.125 M. Subsequently, the lysed cells
were isolated and sonicated on ice to shear DNA into
fragments of 200 bp to 1 kb. Chromatin complexes were
collected using EZ-Chip Chromatin Immuno-precipitation
kit (Millipore) according to the manufacturers’ instructions.
The chromatin was immune-precipitated for 16 h at 4°C
using anti-Sp1, anti-c-Myc antibodies, and normal IgG
(Millipore) as indicated. The input DNA was isolated from
the sonicated lysates before immuno-precipitation as a
positive control. The immune complexes were collected
with Protein A/G Plus agarose (Pierce, Rockland, IL, USA),
and the cross-links were then reversed by heating the
samples at 65°C for 4 h. Purified DNA was then treated
with proteinase K at 42°C for 1 h, and ChIP-PCR was
performed as described.
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Statistical analyses were performed with SPSS version
13.0 (SPSS, Chicago, USA). Quantitative results are
presented as the mean ± standard deviation (SD), and
statistical analyses were carried out by t-tests. The Pear-
son χ2 test was performed to compare the frequency of
survivin overexpression between paired AML patients
with CD34+ and CD34- cell subsets. Associations between
the protein level and continuous variables were assessed
using Pearson’s and Spearman’s correlation and linear re-
gression analyses. Correlations between the levels of Sp1,
c-Myc, and survivin were assessed with Spearman’s ana-
lysis. Differences with P values of less than 0.05 were con-
sidered significant (*P < 0.05 and **P < 0.01).
Additional files
Additional file 1: Figure S1. Isolation and Identification of LSCs. (A) Six
leukemia cell lines were selected and identified with the surface marker
of CD34 and CD38. (B) KG-1a and MOLM13 cells were enriched in LSCs
(9.6% and 4.3%, respectively). (C) Flow cytometry analysis for P-gp expression
of CD34+CD38-, CD34+CD38+, CD34-CD38+, CD34-CD38- in KG-1a cells (D)
Serum-free culture of LSCs from KG-1a cell. (E) Stem-cell-related genes and
drug resistance gene (ABCB1) were detected by qPCR (*P<0.05). (F) The
self-renewal ability of LSCs was detected within soft agar assay, and
re-stained for CD34-PE/CD38-FITC in 4 subpopulations after 14 days by
flow cytometry.
Additional file 2: Figure S2. The LSCs property of drug-resistance.
(A) LSC displayed more chemo-resistance ability than Bulk cells with the
three first-line AML chemotherapeutics Ara-C, Dexamethasone (Dex) and
L-Asparaginase (L-Asp). (B) KG-1a-LSCs and Non-LSC were treated with
Arc-C and Dex in the presence of Verapamil (*P<0.05, **P<0.01). (C) The
columnar statistical chart were analyzed for the apoptosis rates in the
cytotoxicity tests.
Additional file 3: Figure S3. The protein micro-assay slides and siRNA
silencing efficiency. (A) The Human Apoptosis Antibody Array G Series.
(B) The siRNA silencing efficiency of Hsp70, survivin, XIAP and IGF-II were
verified by Western-blottig, and highest silence sequences were listed
below the band. (C) Ectopic expression of pcDNA-Sp1/c-Myc vector was
detected by western blot, and GAPDH was used as internal control.
Additional file 4: Table S1. Primers for amplification of survivin
promoter region. Table S2. Primers for mutation in survivin promoter.
Table S3. Chip Primers and qPCR Primers.
Additional file 5: Figure S4. Inhibiting of Sp1 and C-myc caused the
chemo-resistance of LSCs. (A-B) MITA could significantly increase the
apoptosis rate induced by Ara-C in both cell lines. (C) MITA could
obviously reduce the colony numbers of LSC in tumor-sphere formation
assay (**P<0.01). (D) MITA treatment repressed the core promoter activity of
V5 plasmid of the survivin promoter (**P<0.01). KG-1a and MOLM13-LSCs
were co-transfected with both pGL4-V5(-218/+170) and Renilla luciferase
plasmid for 12 h, exposed to 200 nM MITA for 48 h, and then subjected to
luciferase assays.
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